Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Fisher & Paykel Healthcare Corp Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$20.07 billion
P/E Ratio
55.22
Dividend Yield
1.12%
Shares Outstanding
587.26 million
Earnings per share
0.739
Dividend per share
0.39
Year To Date Return
5.54%
Earnings Yield
1.81%
Franking
N/A
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Fisher & Paykel Healthcare Corp Ltd (ASX: FPH)
Latest News
Healthcare Shares
Buy Pro Medicus and these ASX healthcare stocks now
Investing Strategies
2 soaring ASX shares that show zero signs of slowing
Broker Notes
Here's a 'shopping list' of this fundie's highest quality ASX stocks
Healthcare Shares
This ASX 200 stock just smashed 52-week highs. Is it still a buy?
Share Gainers
Here are the top 10 ASX 200 shares today
Share Market News
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Dividend Investing
10 ASX shares that have raised dividends for a decade
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Broker Notes
4 ASX 200 shares receiving broker upgrades
Share Gainers
Here are the top 10 ASX 200 shares today
Frequently Asked Questions
-
Yes, Fisher & Paykel Healthcare has historically paid two unfranked shareholder dividends a year.
-
Fisher & Paykel Healthcare generally pays its shareholder dividends in July and December.
-
Yes, Fisher & Paykel Healthcare has a dividend reinvestment plan which allows eligible shareholders in New Zealand, Australia, and the United Kingdom to reinvest all or part of their cash dividends in additional ordinary shares free of brokerage fees.
-
Yes, Fisher & Paykel Healthcare Corporation Ltd is listed on the ASX and the New Zealand Exchange.
-
Fisher & Paykel Healthcare Corporation Ltd listed on the ASX on 21 November 2001.
FPH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Fisher & Paykel Healthcare Corp Ltd
Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) is among the world's major designers and manufacturers of respiratory devices. These include products and systems covering in-hospital respiratory care, acute care, and the treatment of obstructive sleep apnea.
The New Zealand-based company earns around 42% of its revenue from the US market and around 30% in Europe. Its hospital products account for about 65% of its revenue with its at-home sleep apnea devices and other respiratory aids accounting for the rest.
Fisher & Paykel invests more than 10% of its operating revenue into its own research and development and has thousands of patents and pending applications. The company has manufacturing facilities in both New Zealand and Mexico.
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Sir Michael Grenfell Daniell | Non-Executive Director | Nov 2001 |
Mr Daniell was Managing Director and Chief Executive Officer of Fisher & Paykel Healthcare from 2001 to 2016. He was General Manager of Fisher & Paykel's medical division from 1990 to 2001 and previously held technical management and product design roles within the company. Mike is a director of Cochlear Limited, Tait International Limited and the Medical Research Commercialisation Fund. He is chair of Quality, Safety & Regulatory Committee and member of People Committee.
|
| Mr Lewis George Gradon | Chief Executive OfficerManaging Director | Apr 2016 |
Mr Gradon spent 15 years as Senior Vice President, Products & Technology, and six years as General Manager, Research & Development. During his 42-year tenure with Fisher & Paykel Healthcare, he has held engineering positions overseeing the development of range of products as well the development of manufacturing, quality, intellectual property, supply chain and clinical research functions.
|
| Mr Neville Mitchell | Non-Executive DirectorNon-Executive Chairman | Nov 2018 |
Mr Mitchell was Chief Financial Officer and Company Secretary of Cochlear Limited between 1995 and 2017. He is a director of Sonic Healthcare and Sigma Healthcare, and a former director of The Board of Tax, South Eastern Sydney Local Health District, Osprey Medical and Sirtex Medical. Previously, he served on the New South Wales Medical Devices Fund, was Chairman of the Group of 100, and Chairman, Standing Committee (Accounting and Auditing) for the Australian Securities and Investments Commission. He is member of Risk Committee, People Committee and Quality, Safety & Regulatory Committee.
|
| Dr Lisa Margaret McIntyre | Non-Executive Director | Oct 2021 |
Dr McIntyre is a director of The University of Sydney, Studiosity, Nanosonics and Baymatob. She has previously been a director of a range of health entities, including those in healthcare insurance, clinical service delivery and medical research and innovation. Lisa spent 20 years as a senior strategy partner with LEK Consulting providing advice to companies in North America, Asia and Australia. She is Chair of People Committee and member of Risk Committee.
|
| Mr Andrew Mark Cross | Non-Executive Director | Oct 2024 |
Mr Cross chairs the board of Chorus and is a director of Xero. He is a board member of Accident Compensation Corporation (ACC) and chair of the ACC Investment Committee. He is a former chair of Milford Asset Management and a former director of Z Energy, Genesis Energy and Argosy Property. Mark previously held executive investment banking positions with Deutsche Bank and Lloyds Corporate Finance/ Southpac Corporation, where he was an advisor to companies across a range of sectors. He is Chair of Risk Committee.
|
| Mr Graham McLean | Non-Executive Director | Oct 2023 |
Mr McLean is chair of both CleanSpace Technology and Universal Biosensors. He previously spent 16 years as an executive at leading medical device manufacturer Stryker Corporation, most recently as President of the Asia Pacific region situated in Hong Kong and Singapore. Prior to joining Stryker, Graham had finance, audit and commercial positions at Lion Nathan, McVitie's and Unilever. He is member of Risk Committee.
|
| Dr Cather Simpson | Non-Executive Director | Jun 2022 |
Dr Simpson is a professor of physics and chemical sciences at the University of Auckland, CEO of Orbis Diagnostics and a partner at Pacific Channel, with experience in lasers and photonics. She is Vice President of the International Society for Optics and Photonics (SPIE) and a member of the Academy Executive Committee of the Royal Society Te Aparangi. Cather is a co founder of three hard-tech start-ups, including Engender Technologies, where she served as Chief Science Officer from 2011 to 2021. She founded and directed the Photon Factory at the University of Auckland in 2010. She is member of Quality, Safety & Regulatory Committee.
|
| Ms Anna Curzon | Non-Executive Director | Feb 2026 |
Ms Curzon brings a knowledge in the technology and financial services industries and is a member of the APEC Business Advisory Council. Currently, Ms Curzon is a director of Gallagher Holdings Limited, Kiwibank and Jade Software Corporation and she chairs the board of Atomic.io. Over her 25-year career, Ms Curzon has served as Managing Director NZ, Chief Partner Officer, and Chief Product Officer at Xero, and she has held leadership or advisory roles with a number of other technology companies.
|
| Ms Raelene Leonard | Company Secretary |
-
|
|
| Lyndal York | Chief Financial Officer |
-
|
|
| Andy Niccol | Chief Operating Officer |
-
|
|
| Raelene Leonard | Company Secretary |
-
|
|
| Desh Edirisuriya | General Manager New Zealand Operations |
-
|
|
| Marcus Driller | Vice President Corporate |
-
|
|
| Nicola Talbot | Vice President Human Resources |
-
|
|
| Nicholas Fourie | Vice President Information & Communication Technology |
-
|
|
| Jonti Rhodes | Vice President Network Design Facilities Infrastructure & Sustainability |
-
|
|
| Dr Andrew Somervell | Vice President Products & Technology |
-
|
|
| Brian Schultz | Vice President Quality Safety & Regulatory Affairs |
-
|
|
| Justin Callahan | Vice President Sales & Marketing |
-
|
|
| Winston Fong | Vice President Surgical Technologies |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Nominees (New Zealand) Limited R601127393 | 72,851,413 | 12.43% |
| JPMorgan Nominees Australia Pty Limited | 57,561,758 | 9.82% |
| HSBC Custody Nominees (Australia) Limited | 56,987,614 | 9.72% |
| HSBC Nominees (New Zealand) Limited R601127385 | 49,522,756 | 8.45% |
| Citicorp Nominees Pty Limited | 45,014,138 | 7.68% |
| JPMorgan Chase Bank | 38,164,940 | 6.51% |
| BNP Paribas Nominees NZ Limited R601338998 | 34,567,359 | 5.95% |
| Citibank Nominees (NZ) Ltd | 26,303,930 | 4.49% |
| Custodial Services Limited | 18,854,845 | 3.22% |
| Tea Custodians Limited | 17,923,982 | 3.06% |
| New Zealand Superannuation Fund Nominees Limited | 14,683,602 | 2.51% |
| Premier Nominees Limited | 7,842,613 | 1.34% |
| Accident Compensation Corporation | 7,828,198 | 1.34% |
| New Zealand Permanent Trustees Limited | 6,561,373 | 1.12% |
| Public Trust | 6,119,187 | 1.04% |
| New Zealand Depository Nominee | 5,708,620 | 0.97% |
| FNZ Custodians Limited | 5,446,374 | 0.93% |
| JBWere (NZ) Nominees Limited | 5,233,917 | 0.89% |
| National Nominees Limited | 4,773,913 | 0.81% |
| BNP Paribas Nominees NZ Limited R601339005 | 4,582,882 | 0.78% |
